BOTHELL, Wash., Feb. 14 /PRNewswire-FirstCall/ -- Lumera Corporation (Nasdaq: LMRA) and The Institute for Systems Biology (ISB) have agreed to collaborate in the development of a high-throughput, label-free detection platform designed to revolutionize proteomics research. The technology platform consists of Lumera's ProteomicProcessor(TM) and NanoCapture(TM) Array technology. The ProteomicProcessor(TM) tool reads Lumera's high density NanoCapture(TM) Microarrays in real-time, without the use of molecular labels. By combining these technologies, researchers will be able to isolate, compile and process vast amounts of data at high-speeds to accelerate proteomic research. Protein-protein, protein-drug, and protein-DNA interactions can be measured with the new system. Real-time kinetics measurements are provided for the binding interactions from complex mixtures on thousands of user-defined spots on the high density NanoCapture(TM) Microarrays. "We are extremely pleased to work with ISB on this exciting proteomics project. We believe that combining NanoCapture(TM) arrays with real-time detection will revolutionize the way and the speed at which proteomics research is done," said Lumera Chief Executive Officer Tom Mino. "Our intention is to bring this technology to market as a user-definable, open platform product family as quickly as possible." "By eliminating the need for labels in a high throughput format, Lumera has removed one of the major road blocks in protein research," said Stephen Lasky, ISB's Director of Technology Development. "Lumera's ProteomicProcessor(TM) has the potential to give us the capability to look at large networks of binding interactions while, at the same time, providing us with specific interaction kinetics of each individual binding event," Lasky continued. "Until now, there has been no feasible method of doing anything like this on a systems-wide level." About Lumera Lumera is an emerging leader in the field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for a broad range of bioscience, electro-optic, and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. For more information, please visit http://www.lumera.com/. Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including in its registrations statement on Form S-1, dated July 22, 2004 and its Quarterly Reports on Form 10-Q.
SOURCE Lumera Corporation